OBJECTIVES: We hypothesized that inhaled nitric oxide (iNO) would not decrease death or neurodevelopmental impairment (NDI) in infants enrolled in the National Institute of Child Health and Human Development Preemie iNO Trial (PiNO) trial, nor improve neurodevelopmental outcomes in the follow-up group. STUDY DESIGN: Infants <34 weeks of age, weighing <1500 g, with severe respiratory failure were enrolled in the multicenter, randomized, controlled trial. NDI at 18 to 22 months corrected age was defined as: moderate to severe cerebral palsy (CP; Mental Developmental Index or Psychomotor score Developmental Index <70), blindness, or deafness. RESULTS: Of 420 patients enrolled, 109 who received iNO (52%) and 98 who received placebo (47%) died. The follow-up rate in survivors was 90%. iNO did not reduce death or NDI (78% versus 73%; relative risk [RR], 1.07; 95% CI, 0.95-1.19), or NDI or Mental Developmental Index <70 in the follow-up group. Moderate-severe CP was slightly higher with iNO (RR, 2.41; 95% CI, 1.01-5.75), as was death or CP in infants weighing <1000 g (RR, 1.22; 95% CI, 1.05-1.43). CONCLUSIONS: In this extremely ill cohort, iNO did not reduce death or NDI or improve neurodevelopmental outcomes. Routine iNO use in premature infants should be limited to research settings until further data are available.
OBJECTIVES: We hypothesized that inhaled nitric oxide (iNO) would not decrease death or neurodevelopmental impairment (NDI) in infants enrolled in the National Institute of Child Health and Human Development Preemie iNO Trial (PiNO) trial, nor improve neurodevelopmental outcomes in the follow-up group. STUDY DESIGN: Infants <34 weeks of age, weighing <1500 g, with severe respiratory failure were enrolled in the multicenter, randomized, controlled trial. NDI at 18 to 22 months corrected age was defined as: moderate to severe cerebral palsy (CP; Mental Developmental Index or Psychomotor score Developmental Index <70), blindness, or deafness. RESULTS: Of 420 patients enrolled, 109 who received iNO (52%) and 98 who received placebo (47%) died. The follow-up rate in survivors was 90%. iNO did not reduce death or NDI (78% versus 73%; relative risk [RR], 1.07; 95% CI, 0.95-1.19), or NDI or Mental Developmental Index <70 in the follow-up group. Moderate-severe CP was slightly higher with iNO (RR, 2.41; 95% CI, 1.01-5.75), as was death or CP in infants weighing <1000 g (RR, 1.22; 95% CI, 1.05-1.43). CONCLUSIONS: In this extremely ill cohort, iNO did not reduce death or NDI or improve neurodevelopmental outcomes. Routine iNO use in premature infants should be limited to research settings until further data are available.
Authors: B R Vohr; L L Wright; A M Dusick; L Mele; J Verter; J J Steichen; N P Simon; D C Wilson; S Broyles; C R Bauer; V Delaney-Black; K A Yolton; B E Fleisher; L A Papile; M D Kaplan Journal: Pediatrics Date: 2000-06 Impact factor: 7.124
Authors: John P Kinsella; Gary R Cutter; William F Walsh; Dale R Gerstmann; Carl L Bose; Claudia Hart; Kris C Sekar; Richard L Auten; Vinod K Bhutani; Jeffrey S Gerdes; Thomas N George; W Michael Southgate; Heather Carriedo; Robert J Couser; Mark C Mammel; David C Hall; Mariann Pappagallo; Smeeta Sardesai; John D Strain; Monika Baier; Steven H Abman Journal: N Engl J Med Date: 2006-07-27 Impact factor: 91.245
Authors: J A Lemons; C R Bauer; W Oh; S B Korones; L A Papile; B J Stoll; J Verter; M Temprosa; L L Wright; R A Ehrenkranz; A A Fanaroff; A Stark; W Carlo; J E Tyson; E F Donovan; S Shankaran; D K Stevenson Journal: Pediatrics Date: 2001-01 Impact factor: 7.124
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Michael D Schreiber; Karen Gin-Mestan; Jeremy D Marks; Dezheng Huo; Grace Lee; Pimol Srisuparp Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: Sjirk Westra; Ira Adler; Daniel Batton; Bradford Betz; Steven Bezinque; Sara Durfee; Kirsten Ecklund; Kate Feinstein; Lynn Fordham; Joseph Junewick; Robert Lorenzo; Roy McCauley; Cindy Miller; Joanna Seibert; Karl Kuban; Elizabeth Allred; Alan Leviton Journal: J Clin Ultrasound Date: 2010-10 Impact factor: 0.910
Authors: George R Conahey; Gordon G Power; Andrew O Hopper; Michael H Terry; Laura S Kirby; Arlin B Blood Journal: Pediatr Res Date: 2008-10 Impact factor: 3.756
Authors: L B DeVries; R J Heyne; C Ramaciotti; L S Brown; M A Jaleel; V S Kapadia; P J Burchfield; L P Brion Journal: J Perinatol Date: 2017-06-15 Impact factor: 2.521
Authors: Gerald S Zavorsky; Arlin B Blood; Gordon G Power; Lawrence D Longo; Raul Artal; Emanuel J Vlastos Journal: Respir Physiol Neurobiol Date: 2010-02-10 Impact factor: 1.931
Authors: Michele C Walsh; Anna Maria Hibbs; Camilia R Martin; Avital Cnaan; Roberta L Keller; Eric Vittinghoff; Richard J Martin; William E Truog; Philip L Ballard; Arlene Zadell; Sandra R Wadlinger; Christine E Coburn; Roberta A Ballard Journal: J Pediatr Date: 2010-02-06 Impact factor: 4.406